title: Nitric oxide signaling via cGMP-stimulated phosphodiesterase in striatal neurons.
abstract: Nitric oxide (NO) acts in the nervous system to activate guanylyl cyclase and increase cGMP. One target for cGMP appears to be the cGMP-stimulated phosphodiesterase (PDE2A), which is widely expressed in the brain and provides a molecular mechanism for NO to regulate cAMP levels. We have found that PDE2A is highly expressed in the medium spiny neurons of the striatum, which project to the pallidum and substantia nigra. These cells express dopamine-stimulated adenylyl cyclase, and we have found that increases in cAMP in these neurons, produced by activation of the D1-type dopamine receptor, are dramatically enhanced by the general phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine and the PDE2A-selective inhibitor erythro-p-(2-hydroxyl-3-nonyl)adenine (EHNA). These results indicate that PDE2A plays a major role in regulating dopamine-stimulated cAMP production in striatal neurons. EHNA also enhances NO-induced increases in striatal cGMP. In addition, dopamine appears to act via another receptor, activated by the agonist SKF83959, to increase striatal cGMP in a NO-dependent manner. Together, these observations indicate that striatal NO producing interneurons can act via the PDE2A in the medium spiny neurons to regulate the cAMP response to dopamine stimulation.
authors.affiliation: Department of Psychiatry, The Brain Research Centre, The University of British Columbia, Vancouver, B.C. V6T1Z3, Canada.
authors.forename: David T S
authors.initials: DT
authors.lastname: Lin
authors.forename: Pascale
authors.initials: P
authors.lastname: Fretier
authors.forename: Cindy
authors.initials: C
authors.lastname: Jiang
authors.forename: Steven R
authors.initials: SR
authors.lastname: Vincent
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D002478:Cells, Cultured; D003342:Corpus Striatum / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D054678:Cyclic Nucleotide Phosphodiesterases, Type 2 / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007395:Interneurons / Q000378:metabolism; D009434:Neural Pathways / Q000378:metabolism; D009474:Neurons / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology
chemical_list: D018491:Dopamine Agonists; D004791:Enzyme Inhibitors; D011954:Receptors, Dopamine; D009569:Nitric Oxide; D054678:Cyclic Nucleotide Phosphodiesterases, Type 2; C517278:Pde2a protein, rat; D000262:Adenylyl Cyclases; D006152:Cyclic GMP; D004298:Dopamine